Overview: Insulin glargine is a long-acting insulin used to lower blood sugar levels in people with diabetes. It helps get sugar into your cells, so your body can use it for energy. The most common ...

Lannett is one step closer to launching biosimilar insulin glargine. Recently, the company completed subject dosing in the pivotal clinical trial of biosimilar insulin glargine, a product being ...

HAMBURG, Germany ― Once-weekly tirzepatide (Mounjaro, Lilly) added to insulin glargine resulted in greater reductions in A1c along with more weight loss and less hypoglycemia compared with prandial ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the second interchangeable insulin glargine biosimilar, Rezvoglar, to improve glycemic control ...

Adding an investigational glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonist to insulin improved glycemic control in ...

A man in his 50s with insulin-treated type 2 diabetes mellitus presented with a 1-day history of severe abdominal pain, nausea and vomiting, 15 days after initiation of tirzepatide. On admission, he ...

Insulin remains one of the most important treatments for people living with diabetes. Whether someone has Type 1 diabetes or advanced Type 2 diabetes, insulin therapy helps control blood sugar levels, ...

TREVOSE, Pa., Aug. 31, 2022 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that subject dosing has been completed in the pivotal clinical trial of biosimilar insulin glargine, a product ...